Actinium-225 Supply Market Report Scope and Overview:

The Actinium-225 Supply Market was valued at USD 218.40 Million in 2025 and is projected to reach USD 2,874.10 Million by 2035, registering a CAGR of 29.4% from 2026 to 2035.

The Actinium-225 Supply Market is revolutionizing the future of targeted cancer therapy by mass producing one of the rarest medicinal radioisotopes to be used in targeted alpha therapy. The market is defined through an increase in the demand for non-carrier added Ac-225 by radiopharmaceutical companies, rise in cyclotron and linear accelerator-based processes for Ac-225 production, rise in radium-226 recycling efforts, and its use in the treatment of prostate cancer, neuroendocrine tumors, and hematologic cancers.

There has been an observed rise in large scale manufacturing of isotopes, partnerships in production in national laboratories, and supply contracts because pharmaceutical companies, national laboratories, and producers of isotope have invested heavily in setting up production facilities that will meet the increasing demand of this precious alpha emitter isotope.

TerraPower Isotopes invested USD 450 million in the construction of a 250,000 sqft cGMP Actinium-225 production plant located in the Bellwether District of Philadelphia during the year 2026, which is anticipated to boost its total production capacity by twenty times from 2029 onwards

Market Size and Forecast

• Market Size in 2026E: USD 282.62 Million

• Market Size by 2035: USD 2,874.10 Million

• CAGR: 29.4% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Actinium-225 Supply Market Trends

• Expanding cyclotron and linear-accelerator production capacity continues easing the isotope's historic global supply bottleneck.

• Growing radium-226 recycling initiatives continue strengthening long-term feedstock security for isotope producers.

• Rising strategic supply agreements between pharmaceutical developers and isotope manufacturers continue locking in dedicated production volume.

• Increasing FDA and EMA regulatory support continues accelerating commercial-scale Ac-225 manufacturing approvals.

• Growing national laboratory investment continues diversifying production beyond finite thorium-229 decay feedstock.

U.S. Actinium-225 Supply Market Outlook

The U.S. Actinium-225 Supply Market was valued at approximately USD 77.40 Million in 2025 and is projected to reach approximately USD 979.10 Million by 2035, registering a CAGR of approximately 28.9% from 2026 to 2035.

The demand in the U.S. was also heavily influenced by high concentration of DOE national laboratories production efforts, substantial investments into development of commercial scale cyclotrons and electron accelerators, and high pharmaceutical industry demand for secured and long-term supply of isotopes.

Enhancing capacity for radium-226 recycling inside the US and growing production of Actinium-225 via Tri-lab accelerators helped to strengthen the position of the US as both biggest producer and biggest addressable market for Actinium-225 globally. Moreover, application of Actinium-225 in the treatment of prostate cancer, leukemia and solid tumors was helping to maintain high demand for this isotope domestically.

NorthStar Medical Radioisotopes confirmed in January 2026 that it had achieved successful routine commercial-scale production of non-carrier-added Actinium-225 using its dedicated electron-accelerator technology, having already supplied the isotope to more than twenty countries worldwide.

Actinium-225 Supply Market Segment Analysis

• By Production Method, Thorium-229 Decay segment dominated the Actinium-225 Supply Market in 2025 with 51% share; Cyclotron-Based Production segment is the fastest growing segment.

• By Purity Grade, Non-Carrier-Added segment dominated the market in 2025 with 64% share; Non-Carrier-Added segment is also the fastest growing segment.

• By Application, Targeted Alpha Therapy segment dominated the market in 2025 with 72% share; Radioimmunotherapy segment is the fastest growing segment.

• By Indication, Prostate Cancer segment dominated the market in 2025 with 44% share; Acute Myeloid Leukemia & Hematologic Malignancies segment is the fastest growing segment.

• By End User, Pharmaceutical & Biopharmaceutical Companies segment dominated the market in 2025 with 39% share; Contract Manufacturing Organizations (CDMOs) segment is the fastest growing segment.

By Production Method, Thorium-229 Decay Leads, While Cyclotron-Based Production Grows Fastest

The Thorium-229 Decay segment had been leading the Actinium-225 Supply Market in 2025, as a result of its proven history of being the most clinically well-known and reliable supplier of Ac-225 to radiopharmaceutical manufacturers. Many decades of use by all sorts of national laboratory facilities including the Tri-Lab accelerator program at Oak Ridge, Los Alamos, and Brookhaven, has instilled great confidence in the product quality and radionuclidic purity generated by this process. Continuous use of legacy thorium-229 generators and the recovery program for uranium-233 stocks in cooperation with the Department of Energy has maintained this method of generation as the gold standard for international supply chain planning despite the fact that there is a natural limit to the supply of its feedstock due to the inability of satisfying ever-growing production demands in the future.

The fastest growing segment in the Actinium-225 Supply Market is expected to be Cyclotron-Based Production as many companies are starting to irradiate radium-226 targets in order to produce non-carrier-added Ac-225 without the need for the limited thorium-229 feedstock. Companies like Eckert & Ziegler, NorthStar Medical Radioisotopes, and the collaboration between Ion Beam Applications and SCK CEN known as PanTera are proving that their cyclotron and electron accelerator approaches are able to create Ac-225 on a weekly cycle. Scale-up of such production sites together with the decrease in production costs per batch and the improvement of radionuclidic purity makes it possible to meet the rising clinical demand.

By Purity Grade, Non-Carrier-Added Ac-225 Dominates and Leads Growth Globally

Non-Carrier-Added segment dominated the Actinium-225 Supply Market in 2025 since pharmaceutical firms need high radionuclidic purity to guarantee dependable radiolabeling activity as well as patient dosimetry. In non-carrier-added Actinium-225, there are no actinium isotopes other than Ac-225, which reduces competing reactions once the radionuclide is attached to peptides or antibodies that target specific disease sites. Moreover, regulatory authorities such as the FDA have embraced the use of non-carrier-added Actinium-225 for the submission of Drug Master Files, and suppliers such as NorthStar and Eckert & Ziegler have emphasized the use of this purity in their production facilities, which use accelerators and cyclotrons.

Non-Carrier-Added purity type is also expected to be the fastest-growing segment within the Actinium-225 Supply market because of accelerated growth in weekly production capacities specifically designed to supply Actinium-225 at the highest available purity level. The growing demand for late-stage actinide-based radiopharmaceuticals requires higher specific activity limits, which can be provided solely by the non-carrier-added isotopic form, thus forcing manufacturers to expand their capacity for producing this purity type of isotope. Improved processes for closed radium-226 recycling and chemical separation increase yields and consistency in non-carrier-added isotopic form manufacturing, consolidating its dual status as the leading revenue generator and the fastest-growing purity type.

By Application, Targeted Alpha Therapy Dominates, Radioimmunotherapy to Grow with Fastest CAGR Globally

Targeted alpha therapy was the largest segment of the Actinium-225 Supply Market in 2025 thanks to the unique characteristics of the isotope's decay that includes multiple high-energy alpha particle emissions for each decay process over a path length of only a few cell diameters. This feature enables radiopharmaceuticals containing Ac-225 isotopes to kill cancer cells while doing little harm to the surrounding healthy tissue. As a result, targeted alpha therapy applications have been developed in programs against metastatic castration-resistant prostate cancer, neuroendocrine tumors, and hematologic malignancies. Clinical success by leading pharmaceutical companies such as Novartis, Bayer, and Telix Pharmaceuticals in developing their targeted alpha therapy programs has further cemented this method as the most widespread clinical application and primary driver of global demand for Ac-225.

Radioimmunotherapy is the most rapidly growing segment of the Actinium-225 Supply Market, owing to the rising number of clinical trials on Ac-225-labeled antibody drugs targeting CD33-positive or other hematologic malignancy markers. The number of clinical programs using Ac-225 along with monoclonal antibodies for treatment of difficult-to-treat leukemias and lymphomas by overcoming the limitations of current radioimmunoconjugate treatments utilizing beta emitters has been increasing steadily. Cooperation between isotope producers and biotech firms, as well as advances in antibody conjugation chemistry, accelerate the clinical development process and make this application segment the most rapidly growing one in the global Ac-225 market.

By Indication, Prostate Cancer Leads, Acute Myeloid Leukemia & Hematologic Malignancies Emerges as Fastest-Growing Segment

The Prostate Cancer segment led the market share in the Actinium-225 Supply Market in 2025 due to metastatic castration-resistant prostate cancer being the most clinically advanced indication for Ac-225 radioligand therapy. There has been significant efficacy observed in patients who were previously treated with chemotherapy, hormonal therapy, and beta-radioligand therapy. Clinical trial advances from developers such as Novartis and Bayer, who have entered into long-term deals to secure Ac-225 supplies, have solidified prostate cancer as the main commercial driver influencing production and capacity plans.

The Acute Myeloid Leukemia & Hematologic Malignancies segment has experienced the highest growth in the Actinium-225 Supply Market as there are advancements in development of Ac-225 labeled antibodies for CD33 as well as other surface markers found in leukemia blasts. Increasing number of patients receiving Ac-225 radioimmunoconjugates as a form of treatment for hematologic malignancies has resulted in increased demand from biotech companies for specialized isotope supplies. Collaboration between national labs and pharmaceutical companies developing therapies for hematologic malignancies is increasing rapidly as well, accelerating enrollment in trials.

By End User, Pharma Companies Dominate, Contract Manufacturing Organizations (CDMOs) Post Fastest Growth Globally

The Pharmaceutical & Biopharmaceutical Companies accounted for the majority share of the Actinium-225 Supply Market in 2025 as major drug companies like Novartis, Bayer, and Telix Pharmaceuticals entered into dedicated, long-term contracts to secure supplies for their late-stage clinical and future commercial pipelines. Major pharmaceutical companies have been actively looking to ensure supply through equity investments and dedicated offtake agreements to ensure access to a perpetually tight supply chain. Increasing understanding that the bottleneck of radioligand therapies is not their clinical performance but isotope availability has resulted in pharmaceutical companies prioritizing their ability to secure supplies strategically and commercially.

The fastest growing end user of the Actinium-225 Supply Market has been the Contract Manufacturing Organizations (CDMOs) end user category as pharmaceutical companies are opting to outsource the processing of isotopes, the radiolabeling process and fill and finish to manufacturing partners who have expertise in radiopharmaceuticals manufacturing. Major manufacturing partners such as Cardinal Health have expanded the number of Ac-225 doses manufactured every week and the number of radiolabeling capabilities to help multiple drug manufacturers at once. Demand for scalable manufacturing partnerships is driving investments in CDMO capacity, making this the fastest-growing end user of Ac-225.

Regional Analysis:

North America Actinium-225 Supply Market Insights

North America dominated the market with the highest share of 41.5% in 2025. The region continued to maintain its leading position owing to the concentration of national laboratory production programs at the Department of Energy, along with active private-sector investments in commercial-scale cyclotrons and electron-accelerator installations. The concentration of isotope production in North America, along with high pharmaceutical demand, ensured its dominance in the market.

The U.S. accounted for an approximate revenue share of 85.40%, mainly driven by the Tri-Lab accelerator initiative, alongside the commercial-scale operations of NorthStar and TerraPower Isotopes. Canada contributed further to the regional strength by virtue of the Radium-226 recycling and production capabilities of Canadian Nuclear Laboratories and the Actineer joint venture.

Europe Actinium-225 Supply Market Insights

Europe also had a sustainable share of the global revenue, owing to effective pharmaceutical regulations in the region, nuclear medicine facilities, and rapid European Medicines Agency approvals of Ac-225-based medications. Momentum towards radium-226 recovery via the IAEA’s Global Radium-226 Management Initiative also helped secure Europe's isotope feedstock sources and diversity of technology used in the region's isotope manufacturing.

Germany was the largest country in terms of demand, with about 26.80% of Europe's revenue, backed up by its dominance of ITM Isotope Technologies Munich, the region's biggest supplier of Ac-225. Other European countries providing significant demand include Belgium and France via the PanTera partnership and Orano Med respectively, while the ongoing regional drive for self-sufficiency in supplies will ensure Europe's Ac-225 demand continues rising through the forecast period.

Asia Pacific Actinium-225 Supply Market Insights

The Asia Pacific region is growing at the fastest rate among all regions reported in this study, fueled by increased national funding for cancer research, investments in radiopharmaceutical manufacture domestically, and increasing number of trials conducted in large healthcare facilities of the region. The combination of building research infrastructure and high unmet oncology need among large numbers of patients in the region ensured that the growth of this region was ahead of all others in this report.

Japan was leading the pack due to the collaborative efforts of national research institutes and cancer treatment centers in developing isotopes within the country. Other countries that played a significant role in ensuring that this was the fastest growing region in this report were China and South Korea.

MEA and Latin America Actinium-225 Supply Market Insights

The Middle East and Africa and Latin America both showed steady growth due to increased developments of nuclear medicine infrastructure, increased funding from the governments for cancer treatment capabilities and increased cooperation between the academic sector and the industry in terms of radioisotope production. The need for targeted alpha therapy using Ac-225 became an increasingly practical solution to cancer burden in these regions, which was inadequately addressed by earlier methods of treatment.

South Africa was the biggest country market within ME&A due to iThemba LABS' well-established production facilities for radioisotopes along with regional investments in nuclear medicine. Additionally, the region experienced contribution of Saudi Arabia to demand in its cancer treatment programs. In LATAM, Argentina was the leading revenue country in the region because of CNEA's production facilities for radioisotopes.

Market Dynamics:

Growth Drivers: Rising Demand for Targeted Alpha Therapy and Expanding Production Capacity

The market is being propelled by increased clinical and commercial demand for targeted alpha therapy, expanded cyclotron and electron accelerator production capabilities, increased recycling of radium-226, and expanding adoption in the pipelines of treatment of prostate cancer, hematological malignancies, and emerging solid tumors. With an ever-increasing number of late-stage radioligand therapy product development programs on the table, the need for consistent supply of high-quality and scalable Ac-225 will continue driving investments in production.

An increasing number of strategic offtake arrangements between pharmaceutical companies and isotope producers adds weight to this trend as the former become increasingly committed to acquiring certain volumes of isotopes ahead of expected market launch. Increasing DOE and national laboratories funding is also helping expand the baseline production capacity, and all these factors combined make for constantly rising demand.

Restraints: Limited Feedstock Availability and Complex Regulatory Approval Pathways

The constant restriction of radium-226 and thorium-229 supply on a global scale remains a true constraint to a quicker expansion of the market as a whole, especially as smaller producers lack the necessary financial budgets for such work which can be provided only by national laboratories and major isotope production companies. This constraint has left the big-scale production in the hands of relatively few well-off organizations.

The complex and multilateral regulatory process required for the production and handling of the newly developed radioisotopes remains another constraint, due to the fact that obtaining licenses for nuclear materials and Drug Master Files in different countries needs coordination of the regulation process which remains an evolutionary one.

Opportunities: Radium-226 Recycling and Expanding Radioligand Therapy Pipelines

Increasing investment into closed-loop radium-226 recycling creates a truly important opportunity because suppliers become less dependent on limited existing feedstock reserves and develop repeatable self-renewing production processes. Suppliers who get ahead in commercial-scale recycling and purification technology can take a big slice of the market as the sector moves from lab scale to true industrial scale production of Ac-225.

A third big opportunity is found in the extension of radioligand therapy development pipeline to other oncology indications, since biotech companies are increasingly targeting Ac-225-labeled compounds in neuroendocrine, hematological and solid tumor diseases. Manufacturers who have demonstrated manufacturing capacity that is compliant with Good Manufacturing Practices can take an important slice of the market as pharma companies increasingly view guaranteed isotope access as a truly important competitive edge.

Recent Developments:

• 2026: Actineer Inc., the joint venture between Canadian Nuclear Laboratories and ITM Isotope Technologies Munich, achieved a closed-loop radium-226 recycling process supporting reliable, industrial-scale Actinium-225 production for global radiopharmaceutical programs.

• 2026: Niowave, Inc. signed a long-term Actinium-225 supply agreement with Novartis AG to support the pharmaceutical company's expanding portfolio of alpha-emitting radioligand cancer therapies.

Actinium-225 Supply Market key players are:

• TerraPower Isotopes

• NorthStar Medical Radioisotopes, LLC

• Oak Ridge National Laboratory (DOE Isotope Program)

• Los Alamos National Laboratory

• Brookhaven National Laboratory

• Eckert & Ziegler Radiopharma GmbH

• BWX Technologies, Inc. (BWXT Medical)

• ITM Isotope Technologies Munich SE

• Actineer Inc.

• Canadian Nuclear Laboratories

• Orano Med

• PanTera GmbH

• Ion Beam Applications SA (IBA)

• Niowave, Inc.

• TRIUMF

• Fusion Pharmaceuticals Inc. (AstraZeneca)

• Telix Pharmaceuticals Limited

• Bayer AG

• Novartis AG

• Cardinal Health, Inc.

Actinium-225 Supply Market Report Scope: